简介：ObjectiveToevaluatetheeffectofdifferentprotocolsofintratympanicdexamethasoneinjectioninpatientswithunilateralsuddensensorineuralhearingloss(SSNHL)whohavefailedtorespondtotypicalmedicaltreatment(includingsystemicsteroidtreatment).MethodsFromJanuary2005toJanuary2008,71patientswhowerediagnosedwithunilateralSSNHLandfailedtypicalmedicaltreatmentreceivedintratympanicdexamethasoneinjection.Fourinjectionprotocolswereemployed:injectionof0.3mldexamethasone(5mg/ml)threetimesaweekfor3weeksforatotaldoseof13.5mg(GroupI,n=16);injectionof0.6ml(5mg/ml)dexamethasonethreetimesaweekfor3weeksforatotaldoseof27mg(GroupII,n=18);injectionat0.3ml(5mg/ml)weekfor6weeksforatotaldoseof9mg(GroupIII,n=18);injectionat0.3ml(5mg/ml)/2daysforatotaldoseof4.5mg(GroupIVn=19).Hearingrecoverywasassessedbypuretoneaudiogram.ResultsThetotaleffectiveratewas37.5%,38.89%,33.33%and36.84%foreachtreatmentprotocol,respectively,withnostatisticaldifferencebetweenthem(P>0.05).Theresultssuggestthatatotaldoseof4.5mg(injectedonceaweekfor3weeks)isthemostadequateprotocol,andincreasingdoseorinjectionfrequencyyieldsnoadditionalbenefits.ConclusionIntratympanicdexamethasonesignificantlyimprovestheprognosisofSSNHL.Smalldoseatlowinjectionfrequencyissufficient.Furthermulticenterstudiesareneededtodeterminethestandardtreatmentprotocol.

简介：Objective:EvaluatingtheauditoryfunctioninpatientswithchronichepatitisCtreatedwithsofosbuvirandribavirin.Methods:Thisstudyinvolved80patientswithchronichepatitisCwhoagreedtoreceivesofosbuvirandribavirin.Allparticipantsweresubjectedtobaselineotologicalandaudiologicalassessmentjustbeforetreatment.Theaudiologicalassessmentincludedstandardpuretoneaudiometry,extendedhighfrequencyaudiometry,immitancemetryandotoacousticemissions(OAEs)(transientanddistortionproduct).Accordingtobaselinehearingthresholdmeasurements,thestudypopulationwasdividedinto2groups.Group1included42patientswithnormalhearingsensitivity(250e8000Hz),andGroup2included38patientswithsensorineuralhearingloss.After24weeksoftherapy,otologicalandaudiologicalassessmentswererepeatedandcomparedbetweenthetwogroupsandbeforeandaftertherapy.Results:Post-treatmenthearingthresholdevaluationshowednosignificantdifferencefrompretreatmentevaluationatalltestedfrequencies.Therewasnostatisticallysignificantdifferencebetweenpreandpost-treatmentotoacousticemissionsresults.Conclusion:TherapywithsofosbuvirandribavirininchronichepatitisChasnonoticeableeffectsoncochlearfunctions.